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and maintain core balance and strength which may 
improve gait and postural stability. Physiotherapy with 
large amplitude physical training improves motor 
function1 and allied health professionals can provide 
specific strategies to overcome disabilities such 
as start hesitancy, freezing of gait, festination and 
falls. Lee Silverman voice training is an established 
technique which has been proven to improve voice 
quality and audibility when patients adhere to the 
long-term strategy.2 Nutrition should be considered in 
all stages of Parkinson’s disease. 
Supportive care is vital in very advanced phases of 
Parkinson’s disease as drugs become poorly tolerated, 
motor fluctuations increase and non-levodopa 
responsive symptoms dominate. Counselling is part 
of the management of non-motor symptoms such as 
anxiety and depression, cognitive dysfunction and 
dementia.
pharmacological management
There are no proven neuroprotective treatments 
for Parkinson’s disease, but drugs are effective in 
symptom control, particularly in the early stages of 
the disorder. Treatment is then increased as required.
When to start treatment
Deciding when to start drug therapy for Parkinson’s 
disease should be individually tailored to a patient’s 
symptoms, circumstances and comorbidities. 
Treatment is indicated when symptoms impact on 
quality of life. When treatment is needed there is no 
evidence to support undue delay because of concerns 
about levodopa toxicity or the development of 
treatment resistance.3 The aim is to control symptoms 
and maintain an ‘on’ state.
Some drugs with good symptomatic benefit are 
speculated to have a role in neuroprotection and 
some specialists advocate their use from the time 
of diagnosis.4 Delayed start trials have been used 
to try and differentiate symptomatic from disease-
modifying effects. A recent delayed start study 
of rasagiline, a monoamine oxidase B inhibitor, in 
treatment-naïve patients with mild Parkinson’s disease 
showed a small benefit in the low-dose (1 mg)  
treatment group. This was not seen with the 2 mg 
dose and a clear explanation for this has not been 
established.5 Further studies are needed before such 
treatments are considered truly disease modifying. 
Until a drug is unequivocally proven to slow disease 
progression, the time to commence treatment will 
remain contentious.
introduction
Parkinson’s disease is a common neurodegenerative 
disorder, which particularly involves the loss of nigral 
dopaminergic neurons. The cardinal motor features 
are rigidity, bradykinesis, rest tremor and postural 
instability. Non-motor features are common both early 
and late in the disease course and include autonomic, 
neuropsychiatric and cognitive disturbances. 
Parkinson’s disease has manifestations beyond the 
nigrostriatal system so it is not surprising that some 
motor features (such as postural instability) and 
many non-motor features have a limited response to 
dopaminergic drugs. 
non-pharmacological management
Non-drug therapies have a significant role in the 
treatment of Parkinson’s disease and include 
counselling and education for both patients and carers. 
This includes providing information about which 
commonly prescribed drugs to avoid, for example 
dopamine-blocking drugs such as metoclopramide, 
prochlorperazine, haloperidol and risperidone. It is 
important to increase general fitness and well-being 
sUMMArY
Parkinson’s disease has a wide variety of 
motor and non-motor symptoms. 
Treatment aims to control the patient’s 
symptoms by replenishing the dopaminergic 
system with levodopa or dopamine agonists. 
Monoamine oxidase B inhibitors are also 
effective first-line drugs. 
Keeping symptoms under continual control 
early in the course of the disease may have 
beneficial effects as Parkinson’s disease 
progresses. 
Therapy is tailored to each patient’s response 
to the drugs and their ability to tolerate them. 
Limited responses of motor and many non-
motor symptoms may require the addition of 
other treatments. 
The adverse effects of drugs used in the 
treatment of Parkinson’s disease are usually 
reversible. 
Symptom fluctuations in response to regular 
medication are an indication for specialist 
referral.
Management of Parkinson’s disease
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Management of Parkinson’s disease
in combination with a dopa-decarboxylase inhibitor, 
a dopamine agonist or a monoamine oxidase B 
inhibitor. Rasagiline would be an appropriate first-line 
drug to consider for those with mild symptoms.
What to start
Motor features of early Parkinson’s disease typically 
respond well to dopamine replacement therapies. The 
choice of drug therapy (Table 1) includes levodopa 
Table 1    drugs to manage motor symptoms of parkinson’s disease
Class of drug Name Adverse effects Comments
Levodopa/dopa-
decarboxylase 
inhibitors
Levodopa/carbidopa 
Levodopa/benserazide 
Nausea, constipation, postural 
hypotension, hypersomnolence, 
sudden sleep episodes, impulse 
control disorders, hypersexuality, 
confusion, hallucinations
Most effective symptomatic treatment
Generally well tolerated and lower adverse effect profile than 
other drugs
Minimum of 3 times daily dosing
Used in early and advanced Parkinson's disease
Controlled-release 
formulations
As above Reduced and variable absorption leads to variable efficacy
Main role is in stabilising nocturnal symptoms
Short-acting formulations As above Used as rescue therapy in advanced Parkinson's disease
Avoid use in early Parkinson's disease – may increase risk of 
motor fluctuations
Enteral levodopa/ 
carbidopa gel suspension 
As above plus complications relating 
to percutaneous enteral tube
Consider in advanced Parkinson's disease where oral therapies 
have failed to control severe motor fluctuations
Dopamine agonists Non-ergot derived:
Pramipexole
Rotigotine patch  
(TGA approved,  
not PBS listed)
Ropinirole (TGA 
approved, not PBS 
listed for Parkinson's 
disease)
Nausea, constipation, postural 
hypotension, hypersomnolence, 
sudden sleep episodes, impulse 
control disorders, hypersexuality, 
confusion, hallucinations, peripheral 
oedema
Good symptomatic therapy
Less dyskinesias/motor fluctuations compared to levodopa
Higher incidence of adverse effects, especially impulse control 
disorders, hypersexuality and neuropsychiatric effects
Available as once-daily dosing in oral and topical forms 
(rotigotine not currently PBS listed)
Ergot derived:
Cabergoline 
Bromocriptine 
Pergolide 
As above plus cardiac valvular 
disease and pleuropulmonary/
retroperitoneal fibrosis
Have been superseded by non-ergot drugs due to risk of fibrotic 
complications
Monitoring essential (interval echocardiograms, respiratory 
function and chest X-ray) for those unable to switch from ergot 
preparations
Apomorphine  
(injection)
As above plus skin nodules,  
skin necrosis
Used as subcutaneous bolus doses for rescue therapy in 
advanced Parkinson's disease with motor fluctuations 
Used as continuous infusion for advanced Parkinson's disease 
with motor fluctuations
Often requires concomitant domperidone to manage nausea
Requires high level of patient/carer support and education
Catechol-O-
methyltransferase 
inhibitor
Entacapone Diarrhoea, nausea, abdominal pain, 
discolouration of urine and sweat
Reduces 'wearing off' symptoms by prolonging the effect of 
levodopa
May induce dyskinesia
Monoamine oxidase 
type B inhibitors
Selegiline 
Rasagiline 
Nausea, hallucinations Both drugs have a putative role in neuroprotection, although no 
conclusive evidence to date
Anticholinergics Benzhexol 
Benztropine 
Confusion, hallucinations, 
memory disturbance, dry mouth, 
constipation, urinary retention, 
glaucoma
Consider for treatment of levodopa-resistant tremor in younger 
patients
No benefit for other motor symptoms
Poorly tolerated in older people
N-methyl-
D-aspartate 
antagonist
Amantadine Hallucinations, confusion, livedo 
reticularis
Main role is in treatment of dyskinesia
Small symptomatic benefit
Tolerability problems
PBS Pharmaceutical Benefits Scheme        TGA Therapeutic Goods Administration
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Levodopa/dopa-decarboxylase inhibitors have the 
highest efficacy for motor symptoms and tend to 
have slightly better tolerability, particularly when 
started in low doses. The simplest dosing regimen is 
to commence a set dose at a set time and thereafter 
monitor the efficacy in terms of the dose required for 
symptom relief and the duration of that response.  
Box 1 shows a typical levodopa dosing regimen. A 
three-times daily starting frequency is required due to 
the short half-life of levodopa. 
As the disease progresses it is important to establish 
the dose that relieves the increasing symptoms. This 
usually requires increasing the frequency of dosing 
from three to four (and often five) times a day  
(Box 2) with the addition of a long-acting preparation 
at bedtime. 
Dopamine agonists are also effective first-line drugs 
and may be associated with less dyskinesia than 
levodopa/dopa-decarboxylase inhibitors. They are 
available in once-daily preparations. Long-term 
data suggest no significant difference in outcomes 
between patients started on levodopa/dopa-
decarboxylase inhibitors and those given dopamine 
agonists.6 It is common as time progresses to use a 
combination of these drugs.4
Adverse effects
All patients should be appropriately counselled 
before treatment and monitored for adverse effects 
throughout their lifelong treatment course. Most 
adverse effects are reversible. Cardiac valvular fibrosis 
and pulmonary fibrosis from the ergot-derived 
dopamine agonists such as cabergoline and pergolide 
may be irrreversible and some cases require surgical 
intervention. This risk seems most apparent amongst 
patients who have had more than six months duration 
of treatment and in those on higher doses of ergot-
dopamine agonists, although individual susceptibility 
factors are not yet known.7 Patients taking these 
drugs require constant monitoring and where possible 
switching to a non-ergot derived dopamine agonist 
such as pramipexole, ropinirole or rotigotine is 
desirable.
Non-motor adverse effects of dopaminergic 
therapy include nausea, postural hypotension, 
cognitive symptoms, hallucinations, psychosis, 
hypersomnolence, sudden sleep episodes and impulse 
control disorders (gambling, compulsive behaviours 
and hypersexuality). Such adverse effects can occur 
with all dopaminergic therapies, although are more 
common with dopamine agonists, which can also 
cause peripheral oedema. The risk of impulse control 
disorders is significantly higher with dopamine 
agonists. Pretreatment counselling and sustained 
clinical vigilance for these disorders is essential. A 
reduced dose of pramipexole is needed in patients 
with impaired renal function and doses should be 
increased cautiously in older people.  
Dopaminergic drugs sometimes increase the non-
motor symptoms of Parkinson’s disease. Many of 
the drugs cause gastrointestinal adverse effects. If 
drug treatment is required for nausea or vomiting, 
metoclopramide and prochlorperazine should be 
avoided due to their dopamine blocking effects. 
Domperidone is the preferred treatment for these 
symptoms.
inadequate response
If the patient’s symptoms are not controlled it is 
important to exclude other diseases. As Parkinson’s 
disease progresses slowly, any sudden deterioration 
is an indicator of a co-existent medical condition, 
such as a urinary tract infection, or problems with 
compliance. Adherence can be a particular problem 
given the frequent dosing schedule of levodopa 
preparations, but may be helped by providing the 
medicines in a multidose pack. 
Box 1    typical regimen for starting 
levodopa *
Step 1: Start at 50 mg 3 times a day for 2 weeks
Step 2: Increase to 100 mg 3 times a day. Continue 
until there is a clinical need for a change in dose. 
This will vary between individuals depending on the 
severity of their Parkinson’s disease (e.g. could range 
from weeks to years).
Step 3: Increase to 150 mg 3 times a day if not  
coming ‘on’
or
change to 100 mg 4 times a day if coming ‘on’ but not 
making it from dose to dose
or
change to 100 mg 3 times a day with entacapone if not 
coming ‘on’ or not making it from dose to dose
or
add pramipexole extended-release once daily if not 
coming ‘on’ or not making it from dose to dose
* Strength refers to levodopa dose alone, regardless 
of whether in combination with a dopa-decarboxylase 
inhibitor/catechol-O-methyltransferase inhibitor
Box 2    typical levodopa dosing times
3 times a day – 6 am/12 pm/6 pm
4 times a day – 6 am/10 am/2 pm/6 pm
5 times a day – 6 am/9 am/12 pm/3 pm/6 pm
A prolonged-release formulation can be used at 
bedtime
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this situation. Dose failures may respond to oral 
rescue therapy with short-acting levodopa/dopa-
decarboxylase inhibitors.
Involuntary motor movements or dyskinesias are 
often not troubling to patients, so they do not always 
require a change of treatment if good ‘on’ time is 
maintained. Disabling dyskinesias may require dose 
reduction at the risk of loss of efficacy. Amantadine 
has a mild to modest benefit in controlling motor 
symptoms and can reduce dyskinesia, however it 
has potential adverse effects including confusion, 
peripheral oedema and livedo reticularis.
treatment options for motor 
complications refractory to oral 
therapies
Specialist referral and co-management of patients 
as time progresses is needed to manage the more 
challenging aspects of motor fluctuations. Non-oral 
therapies including apomorphine, intestinal levodopa 
infusion and deep brain stimulation can be considered 
when standard drug therapy fails to effectively 
manage motor fluctuations. All these treatments 
require ongoing involvement of a multidisciplinary 
team experienced in managing advanced Parkinson’s 
disease. 
Apomorphine
Apomorphine is an injectable dopamine agonist 
which can be given as intermittent bolus doses or 
by continuous subcutaneous infusion. Intermittent 
boluses are effective rescue therapy for disabling 
motor ‘off’ symptoms, while continuous infusion can 
reduce daily ‘off’ time and reduce the required doses 
of oral drugs.11 Apomorphine has the same potential 
adverse effects as oral dopamine agonists and 
may cause injection site reactions and skin nodules. 
Patients may need domperidone to prevent vomiting.
Intestinal levodopa infusion
Continuous administration of levodopa/dopa-
decarboxylase inhibitors in gel form via a 
percutaneous enteral tube is available for advanced 
Parkinson’s disease with severe motor fluctuations 
refractory to oral therapy. Typically, patients carry 
an infusion pump around the waist or across the 
shoulder allowing continuous infusion during waking 
hours, with the option to extend to a 24-hour infusion 
to cover nocturnal symptoms if required. It overcomes 
complications relating to variable absorption of 
levodopa secondary to delayed gastric emptying 
and protein consumption. Usually, oral therapy can 
be withdrawn. Several studies, including some small 
randomised controlled trials have shown improvement 
in motor function, motor fluctuations and quality of 
life. Complications include all those seen in standard 
Sustained failure to achieve adequate symptom 
control with a particular levodopa or dopamine 
agonist regimen should prompt an increase in the 
dose of that drug or consideration of combination 
therapy. 
A fluctuating or erratic treatment response in early 
Parkinson’s disease may reflect variable absorption of 
oral therapy. Separating levodopa therapy from meals 
can improve absorption. Consideration of drugs which 
provide more continuous dopaminergic stimulation 
such as once-daily pramipexole or the rotigotine 
patch may be helpful. 
Nocturnal symptoms are often improved with 
the addition of long-acting dopamine agonists 
(particularly if the patient has restless legs) or 
controlled release levodopa/dopa-decarboxylase 
inhibitors. Non-motor symptoms such as nocturia may 
also need to be addressed (Table 2). 
Some patients with tremor refractory to levodopa 
therapy may respond to dopamine agonists. 
Anticholinergic drugs can cautiously be tried in 
younger patients and are occasionally useful in 
reducing saliva production. However, they can 
have significant cognitive adverse effects such as 
hallucinations, particularly in older people.  
treatment of motor fluctuations and 
dyskinesia
Motor and non-motor fluctuations occur as 
Parkinson’s disease progresses. This can make 
drug therapy challenging.10 Fluctuations include the 
return of symptoms at the end of the dose interval 
(‘wearing off’), failed symptom relief and sudden 
and unpredictable ‘offs’ of both motor and non-
motor type. Increased dosing is also associated 
with so-called drug-induced dyskinesias resembling 
choreiform movements which occasionally can be 
localised, but generalise as the disorder progresses. 
These can occur in peak dose and diphasic* patterns.
‘Wearing off’ between doses can be managed by 
increasing the dose, reducing the dose interval (if 
using levodopa/dopa-decarboxylase inhibitors) or 
adding other drugs. Entacapone is a further inhibitor 
of levodopa breakdown and in combination with 
levodopa/dopa-decarboxylase inhibitors reduces 
‘wearing off’ and increases the potency of an 
individual dose of levodopa. Often a dose reduction 
of approximately 25% is needed when entacapone 
is added. Dopamine agonists are also useful in 
smoothing out the end-of-dose ‘wearing off’ effect by 
reducing the severity of the ‘off’ period. Monoamine 
oxidase B inhibitors can also be considered in 
* Diphasic dyskinesia occurs as the levodopa 
concentration rises and then falls
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Table 2    Management of non-motor features of parkinson’s disease
Non-motor manifestation Management options
Cardiovascular Postural and postprandial 
hypotension
Increased fluid and salt intake, frequent small meals, compression stockings (above knee)
Avoid antihypertensives
Domperidone +/– fludrocortisone
Pyridostigmine
Midodrine (Special Access Scheme only)
Gastrointestinal Constipation Good hydration, high fibre diet, laxatives
Avoid anticholinergics
Gastroparesis (nausea, 
bloating, abdominal pain, 
early satiety)
Postural advice, frequent small meals
Domperidone
Dysphagia and dysphonia Speech therapy assessment, Lee Silverman voice training
Dopaminergic therapy – may be partially levodopa responsive
Drooling Dopaminergic therapy
Anticholinergics (beware adverse effects)
Salivary gland botulinum toxin injections
Genitourinary Urinary irritability  
(frequency, urgency, urge 
incontinence, nocturia)
Avoid diuretics including coffee
Perform post-void bladder scan to rule out retention before starting therapy
Oxybutynin, amitriptyline, tolterodine, prazosin, duloxetine
Erectile dysfunction Dopamine agonists
Sildenafil or similar oral therapy – check for postural hypotension before prescribing
Specialist referral for counselling/consideration of intracavernosal and surgical treatments
Neuropsychiatric 
and cognitive
Anxiety 'Off' state anxiety may respond to an increase in dopaminergic therapy
Antidepressants (tricyclics or selective serotonin reuptake inhibitors)
Counselling, support, psychotherapy
Depression Counselling, support, psychotherapy
Dopamine agonists may have antidepressant properties8
Antidepressants (tricyclics or selective serotonin reuptake inhibitors)
Psychosis Non-troubling hallucinations do not require drug treatment
For distressing hallucinations/paranoia:
 • exclude treatable causes of delirium
 • modify Parkinson's disease drug therapies (reduce or cease anticholinergics, monoamine oxidase 
B inhibitors, amantadine, dopamine agonists, catechol-O-methyltransferase inhibitors)
 • reduce levodopa if no response
 • quetiapine appears to have a relatively low incidence of extrapyramidal effects (clozapine has 
less extrapyramidal effects but its use is limited by adverse effects and need for monitoring)
Cognitive impairment Manage as for distressing psychosis 
Cholinesterase inhibitors improve cognition and activities of daily living in Parkinson's disease 
dementia,9 but are currently only approved in Australia for Alzheimer's dementia
Sleep Excessive daytime sleepiness Rule out other causes of ineffective sleep (e.g. sleep apnoea, depression, nocturia, inadequately 
controlled Parkinson's disease motor symptoms)
Reduce dopaminergic therapy if possible
Sleep attacks may necessitate reduction of dopaminergic therapy at expense of motor control
Restless legs syndrome Dopaminergic therapy
REM sleep behaviour disorder Clonazepam 
Pain Pain/sensory symptoms Establish whether present during a motor 'on' or 'off' state and adjust dopaminergic therapy 
appropriately
If unrelated to dopaminergic therapy, consider simple analgesics, drugs for neuropathic pain, 
antidepressants, chronic pain management strategies
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oral levodopa therapy. Additional complications 
related to the technical aspects of the infusion system, 
including tube removal/dislocation, local infection, 
peritonitis and intestinal obstruction, are reported in 
20–70% of patients.12
Functional neurosurgery
There are two main neurosurgical options for 
Parkinson’s disease. The first is lesional surgery, which 
permanently ablates a target region to achieve either 
tremor control or lessen dyskinesia. The second is 
deep brain stimulation surgery. This is reversible and 
provides continuous electrical stimulation to a target 
from an implanted pulse generator (battery) which 
is adjustable via an externally applied programmer. 
Several randomised controlled trials have shown deep 
brain stimulation improves motor symptom control, 
reduces motor fluctuations and improves quality of 
life in people with advanced Parkinson’s disease.13-15 
Sustained motor benefit over 10 years has been 
demonstrated.16 Often dopaminergic drug therapy 
can be significantly reduced following deep brain 
stimulation which is of particular benefit when the 
drugs are difficult to tolerate. 
Both forms of functional neurosurgery carry 
immediate perioperative risk and deep brain 
stimulation carries additional risks associated 
with the implanted hardware and stimulation field 
effect. Deep brain stimulation is not a cure, and 
inevitably symptoms of Parkinson’s disease progress, 
but possibly at a slower rate.17 Australian referral 
guidelines for deep brain stimulation are available.18
Management of non-motor symptoms
Patients with Parkinson’s disease may have 
autonomic dysfunction, neuropsychiatric symptoms 
and cognitive impairment. Non-motor symptoms 
contribute significantly to the morbidity of Parkinson’s 
disease. Interestingly, some of these are present as 
part of the ‘off’ phenomena and remain responsive to 
levodopa, but many are not and warrant management 
in their own right. Adverse effects of dopaminergic 
therapies often overlap with non-motor symptoms 
so the combined opinion of movement disorder 
specialists, neuropsychiatrists and other specialists is 
often important. Common non-motor problems and 
possible treatment options are outlined in Table 2.
Conclusion
Parkinson’s disease is a progressive neurological 
disorder with motor and non-motor features. It has 
significant cost and burden of care to the community 
over a prolonged course. Treatment is aimed at 
maintaining continuous relief of motor and non-motor 
symptoms. Drugs may be necessary, but are not 
sufficient to maintain quality of life in the long term. 
As the disease progresses, specialist referral and allied 
health involvement is important. The patient will need 
collaborative assistance from general practitioners, 
movement disorder specialists, neuropsychiatrists and 
allied health professionals.  
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Self-teSt 
queStionS
True or false? 
3. Levodopa therapy 
should be delayed as 
long as possible as it 
is only effective for a 
limited time. 
4. Dopaminergic 
therapy may 
exacerbate the non-
motor symptoms of 
Parkinson’s disease.
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